

Tozinameran

S

Various toxicities: 7 case reports

In a study involving 414 patients, seven patients (1 man and 6 women) aged 24-54 years were described who developed angioedema, pruritus, urticaria, hypotension, skin rash or itching following coronavirus disease 2019 (COVID-19) vaccination with tozinameran. The hypotension was attributed to polyethylene glycol and polysorbate 80 which were used as an excipient in tozinameran.

The patients, who had received tozinameran [BNT162B2; *route and dosage not stated*] for COVID-19, developed unilateral left eyelid angioedema (1 patient), urticaria characterised with wheals localised mainly at lower limbs and face (1 patient), bilateral eyelid angioedema and pruritus localised at neck and face (1 patient), urticaria characterised by wheals localised mainly upper limbs and face (1 patient), hypotension (1 patient), unilateral right eyelid and labial angioedema (1 patient) and widespread itching after the first dose at 20 minutes-24 hours.

Subsequently, the hypersensitivity reactions of six patients regressed and they received second dose of tozinameran. One patient, who developed hypotension, tested positive for both polyethylene glycol and polysorbate 80 allergy tests; hence, the patient was excluded from the second dose administration.